HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023

$ 1499


Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV virus, thereby reducing the risk of its transmission. According to the latest report by IMARC Group, titled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023”, the global HIV drugs market exceeded a value of US$ 17 Billion in 2017.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, the market value is projected to reach approximately US$ 21 Billion by 2023, expanding at a CAGR of more than 3% during 2018-2023.

HIV Drug Market Report

Market Summary:

  • Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
  • On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
  • Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global share.
  • The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.


This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.

Key Questions Answered in This Report:

  • How has the global HIV drugs market performed so far and how will it perform in the coming years?
  • What are the key regions in the global HIV drugs market?
  • Which are the popular class types in the global HIV drugs market?
  • What are the major distribution channels in the global HIV drugs market?
  • What are the various stages in the value chain of the global HIV drugs market?
  • What are the key driving factors and challenges in the global HIV drugs market?
  • What is the structure of the global HIV drugs market and who are the key players?
  • What is the degree of competition in the global HIV drugs market?
  • How are HIV drugs manufactured?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global HIV Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Price Analysis
    5.4    Market Breakup by Drug Class
    5.5    Market Breakup by Distribution Channel
    5.6    Market Breakup by Region
    5.7    Market Forecast
    5.8    SWOT Analysis
        5.8.1    Overview
        5.8.2    Strengths
        5.8.3    Weaknesses
        5.8.4    Opportunities
        5.8.5    Threats
    5.9    Value Chain Analysis
        5.9.1    Overview
        5.9.2    Research and Development
        5.9.3    Raw Material Procurement
        5.9.4    Manufacturing
        5.9.5    Marketing
        5.9.6    Distribution
        5.9.7    End-Use
    5.10    Porters Five Forces Analysis
        5.10.1    Overview
        5.10.2    Bargaining Power of Buyers
        5.10.3    Bargaining Power of Suppliers
        5.10.4    Degree of Competition
        5.10.5    Threat of New Entrants
        5.10.6    Threat of Substitutes
6    Market Breakup by Drug Class
    6.1    Nucleoside Reverse Transcriptase Inhibitors 
    6.2    Multi-Class Combination Products 
    6.3    Protease Inhibitors
    6.4    HIV Integrase Strand Transfer Inhibitors 
    6.5    Non-Nucleoside Reverse Transcriptase Inhibitors 
    6.6    Entry Inhibitors — CCR5 Co-Receptor Antagonist 
    6.7    Fusion Inhibitors 
7    Market Breakup by Distribution Channel
    7.1    Hospital Pharmacies
    7.2    Retail Pharmacies
    7.3    Online Pharmacies
    7.4    Others
8    Market Breakup by Region
    8.1    North America
    8.2    Europe
    8.3    Asia Pacific
    8.4    Middle East and Africa
    8.5    Latin America
9    HIV Drugs Manufacturing Process
    9.1    Product Overview
    9.2    Raw Material Requirements
    9.3    Manufacturing Process
    9.4    Key Success and Risk Factors
10    Competitive Landscape
    10.1    Market Structure
    10.2    Key Players
    10.3    Profiles of Key Players
        10.3.1    Boehringer Ingelheim International GmbH
        10.3.2    Merck & Co., Inc. 
        10.3.3    ViiV Healthcare
        10.3.4    AbbVie
        10.3.5    F. Hoffmann-La Roche Ltd. 
        10.3.6    Teva Pharmaceutical Industries Ltd. 
        10.3.7    Bristol-Myers Squibb 
        10.3.8    Gilead Sciences, Inc. 
        10.3.9    Johnson & Johnson
        10.3.10    Cipla Limited 
        10.3.11    Daiichi Sankyo 
        10.3.12    Emcure 
        10.3.13    Hetero Drugs 
        10.3.14    Mylan

List of Figures

Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2010-2017
Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2017
Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2017
Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2017
Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2018-2023
Figure 7: Global: HIV Drugs Industry: SWOT Analysis
Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
Figure 9: Global: HIV Drugs Industry: Porter’s Five Forces Analysis
Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 11: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 12:Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 13:Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 14:Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 15:Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 16: Global: HIV Drugs (Fusion Inhibitors) Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 17: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2010, 2017 & 2023
Figure 18: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2010, 2017 & 2023
Figure 19: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2010, 2017 & 2023
Figure 20: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2010, 2017 & 2023
Figure 21: Europe: HIV Drugs Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 22: North America: HIV Drugs Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 23: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 24: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 25: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2010, 2017 & 2023
Figure 26: HIV Drugs Manufacturing: Process Flow

List of Tables

Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2017 and 2023
Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2018-2023
Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2018-2023
Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2018-2023
Table 5: HIV Drugs: Raw Material Requirements
Table 6: Global: HIV Drugs Market Structure
Table 7: Global: HIV Drugs Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Special Prices


    IMARC provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations
  • For more information, feel free to contact us.